Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Files An 8-K Financial Statements and ExhibitsItem 9.01
(d) The following exhibits are included in this report:
|
Exhibit No. |
Description |
| 99.1 | Press release issued by the Company and Celgene on August 1, 2017. |
AGIOS PHARMACEUTICALS INC ExhibitEX-99.1 2 d401434dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 FDA GRANTS APPROVAL OF IDHIFA®,…To view the full exhibit click here
About Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. Its cancer product candidates are AG-221 and AG-120, which targets mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. The lead product candidate in its RGD programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Its AG-221 is an orally available, selective, inhibitor of the mutated IDH2 protein indicated for the treatment of patients with cancers. Its AG-120 is an orally available, selective, inhibitor of the mutated isocitrate dehydrogenase (IDH1) protein for the treatment of patients with cancers. AG-881 is an orally available, selective, brain-penetrant, pan-IDH mutant inhibitor.
